Business Description
Egetis Therapeutics AB
ISIN : SE0003815604
Total Employee Number:
44Compare
Compare
Traded in other countries / regions
EGTX.Sweden0ABW.UKP0F.GermanyPDPHF.USA IPO Date
2017-05-26Description
Egetis Therapeutics AB is an integrated pharmaceutical drug development company, focusing on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.03 | |||||
Equity-to-Asset | 0.46 | |||||
Debt-to-Equity | 0.28 | |||||
Debt-to-EBITDA | -0.2 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -2.47 | |||||
Beneish M-Score | -1.94 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 12.9 | |||||
3-Year EBITDA Growth Rate | 7.5 | |||||
3-Year EPS without NRI Growth Rate | 2.9 | |||||
3-Year FCF Growth Rate | 7 | |||||
3-Year Book Growth Rate | -28.6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 142.07 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.69 | |||||
Quick Ratio | 0.68 | |||||
Cash Ratio | 0.6 | |||||
Days Inventory | 9.83 | |||||
Days Sales Outstanding | 125.09 | |||||
Days Payable | 159.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -22.6 | |||||
Shareholder Yield % | 1.02 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 14.24 | |||||
Operating Margin % | -583.86 | |||||
Net Margin % | -592.09 | |||||
EBITDA Margin % | -562.82 | |||||
FCF Margin % | -422.04 | |||||
OCF Margin % | -420.17 | |||||
ROE % | -113.21 | |||||
ROA % | -59.39 | |||||
ROIC % | -61.18 | |||||
3-Year ROIIC % | -82.34 | |||||
ROC (Joel Greenblatt) % | -3487.25 | |||||
ROCE % | -88.99 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 9.93 | |||||
PS Ratio | 31.69 | |||||
PB Ratio | 8.36 | |||||
EV-to-EBIT | -6.67 | |||||
EV-to-EBITDA | -6.67 | |||||
EV-to-Revenue | 37.55 | |||||
EV-to-FCF | -8.91 | |||||
Price-to-GF-Value | 0.99 | |||||
Earnings Yield (Greenblatt) % | -14.99 | |||||
FCF Yield % | -10.9 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:PDPHF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Egetis Therapeutics AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 6.739 | ||
| EPS (TTM) ($) | -0.095 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR ($) | - | ||
| 20-Day SMA ($) | 0.6353 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 0.6353 - 0.6353 | ||
| Shares Outstanding (Mil) | 464.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Egetis Therapeutics AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Egetis Therapeutics AB Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-25 07:00 | In 154 days | ||
| Second quarter earnings results for 2026 | 2026-08-21 | In 57 days | ||
| First quarter earnings results for 2026 | 2026-04-29 07:00 | 0.64 (+0.00%) | ||
| General meeting for 2026 | 2026-04-14 14:00 | -- | ||
| Annual report for 2025 | 2026-03-24 | -- | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 07:00 | -- | ||
| Third quarter earnings results for 2025 | 2025-11-25 07:00 | -- | ||
| Second quarter earnings results for 2025 | 2025-08-21 | -- | ||
| General meeting for 2025 | 2025-05-06 15:30 | -- | ||
| First quarter earnings results for 2025 | 2025-04-30 07:00 | -- |
Show
Entries
Egetis Therapeutics AB Frequently Asked Questions
What is Egetis Therapeutics AB(PDPHF)'s stock price today?
The current price of PDPHF is $0.64. The 52 week high of PDPHF is $0.64 and 52 week low is $0.64.
When is next earnings date of Egetis Therapeutics AB(PDPHF)?
The next earnings date of Egetis Therapeutics AB(PDPHF) is 2026-08-21 Est..
Does Egetis Therapeutics AB(PDPHF) pay dividends? If so, how much?
Egetis Therapeutics AB(PDPHF) does not pay dividend.
Guru Commentaries on OTCPK:PDPHF
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Egetis Therapeutics asks for hugs to increase disease awareness of MCT8 deficiency | 2022-02-24 |
Articles on Egetis Therapeutics AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers